FDA Committees Weigh the Risks and Benefits of Esketamine for TRD (2019)
Introduction: In 2019, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) evaluated […]
Condition
Esketamine: A New Hope for Treatment-Resistant Depression (FDA Advisory Committees, 2019)
Introduction: The FDA reviewed a new treatment called esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). TRD
Ketamine and Esketamine Trials for TRD: A Clinical Update (Duke Scholars, January 2023)
Introduction: Ketamine and esketamine are increasingly investigated for their potential in managing TRD. This systematic review examines clinical trials registered
Ketamine and Esketamine for Depression: Promising Hope for Tough Cases (Duke Scholars, January 2023)
Introduction: Ketamine and esketamine have been explored in medical research for treating treatment-resistant depression (TRD), a severe form of depression
Ketamine and Esketamine: Emerging Indications and Mechanisms, Oct 2024 Review
Introduction The study by Vekhova et al. (Oct 2024) presents a comprehensive review of ketamine and esketamine’s evolving role in
New Hope for Mental Health: Ketamine and Esketamine Research Trends, Oct 2024
Introduction A recent study by Vekhova, Namiot, Jonsson, and Schiöth (Oct 2024) explores the growing use of ketamine and esketamine
Sex Differences in Ketamine’s Antidepressant Efficacy and Abuse Liability: Insights from Wright & Kabbaj, 2018
Introduction: Wright and Kabbaj (2018) examined sex-specific differences in ketamine’s sub-anesthetic antidepressant effects and abuse liability, emphasizing the importance of
Ketamine’s Role in Depression: How Gender Influences Effects and Risks – Insights from Wright & Kabbaj’s 2018 Study
Introduction: In their 2018 study, researchers Wright and Kabbaj explored how ketamine’s antidepressant effects and potential for misuse differ between
Navigating Hope and Hype: Ketamine Clinics and TRD – Insights from Thielking’s 2018 STAT Report
Introduction: Megan Thielking’s STAT News article sheds light on the burgeoning industry of ketamine clinics, examining their promise in treating
Ketamine for Depression: Hope and Hype – A Look at Thielking’s 2018 Report on Clinics and Care
Introduction: In 2018, reporter Megan Thielking explored the growing trend of ketamine treatments for severe depression in her STAT News